头孢哌酮钠舒巴坦钠治疗脑卒中相关性肺炎的临床疗效及对细菌清除率的影响

Clinical Effect of Sulbactam and Cefoperazone on Apoplexy-associated Pneumonia and Bacterial Clearance

目的:探讨头孢哌酮钠舒巴坦钠治疗脑卒中相关性肺炎的临床效果,促进患者康复质量。方法:选择符合标准的患者80例,随机分为观察组和对照组各40例,观察组给予头孢哌酮钠舒巴坦钠,对照组应用头孢他啶,疗程7d,观察两组患者临床症状、体征及实验室检查结果变化情况。结果:观察组患者退热时间、咳嗽及咳痰缓解时间、啰音消失时间、胸部X线片炎症消失时间及白细胞计数恢复正常时间较对照组均缩短,差异有统计学意义(P<0.05)。治疗7d后,观察组患者治愈19例、显效12例、进步7例和无效2例,对照组患者治愈13例、显效9例、进步10例和无效8例,差异有统计学意义(P<0.05)。观察组患者痰培养分离出细菌32株、清除28株、清除率为87.50%;对照组分离出30株、清除21株,清除率为70.00%,差异有统计学意义(P<0.05)。结论:头孢哌酮钠舒巴坦钠可以有效控制脑卒中相关性肺炎患者的临床症状,减轻炎症反应,有效清除致病菌,提高临床治疗效果,值得临床推广应用。

Objective： To investigate the clinical effect of sulbactam and cefoperazone on apoplexy-as- sociated pneumonia, and to promote the quality of rehabilitation in the patients. Method ： A total of 80 eligi- ble patients were selected, and randomly divided into observation group and control group, with 40 patients in each group. The observation group was given with sulbactam and cefoperazone, while the control group was given with ceftazidime, the courses were 7 days for both groups. The changes in clinical symptoms, physical signs, and laboratory examination results of the two groups were observed. Result： The patients of the obser- vation group had shorter fever clearance time, time to release of cough and expectoration, time to disappear- ance of rales, time to disappearance of chest inflammation as revealed by X-ray films, and time to recovery of WBC count than the control group, and the differences were statistically significant （all P〈0.05）. At 7 days after the treatment, In the observation group, 19 patients were cured, 12 were responsive to the therapy excellently, 7 were improved, and 2 were unresponsive to the therapy; while of the control group, 13 pa- tients were cured, 9 were responsive to the therapy excellently,10 were improved, and 8 were unresponsive to the therapy; and the differences were statistically significant （P〈0.05）. Of the patients in the observation group, 32 strains were isolated after sputum culture, 28 were cleared, and the clearance was 87.50% ; while of the patients of the control group, 30 strains were isolated, 21 were cleared, and the clearance was 70. 00%; and the difference was statistically significant （P〈0.05 ）. Conclusion： Sulbactam and cefoperazone can effectively control the clinical symptoms, lighten inflammatory reactions, clear pathogenic bacteria, and elevate clinical effect in patients with apoplexy-associated pneumonia, and consequently is worthy of clinical application.